# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 2541-2550 of 2712 results.
Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy
Status: Unknown status
Last Changed: Feb 24, 2017
First Received: Nov 27, 2014
Disease(s): Carcinoma
Locations: Practice, Mannheim, Germany
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Status: Recruiting
Last Changed: Jun 12, 2020
First Received: Jul 26, 2018
Disease(s): Locally Advanced or Metastatic Solid Tumor
Intervention(s): rebastinib, Paclitaxel
Locations: University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
Scripps Health, San Diego, California, United States
University of Colorado Denver- Anschutz Medical Center, Aurora, Colorado, United States
Smillow Cancer Hospital Care Center at Trumbull, Trumbull, Connecticut, United States
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
... and 14 other locations.
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Status: Recruiting
Last Changed: Jul 31, 2020
First Received: Jul 24, 2020
Disease(s): Solid Tumor, Adult
Intervention(s): TTX-080
Locations: Nebraska Cancer Center Oncology Hematology West P.C., Omaha, Nebraska, United States
NEXT Oncology, San Antonio, Texas, United States
Study of Intermittent OSI-906 Dosing
Status: Completed
Last Changed: Jan 30, 2019
First Received: Aug 09, 2007
Disease(s): Advanced Solid Tumors
Intervention(s): OSI-906
Locations: MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Unit, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
Genetically-informed Therapies for Patients With Metastatic Cancer
Status: Withdrawn
Last Changed: Jul 14, 2014
First Received: Dec 04, 2013
Disease(s): Metastatic Cancer
Intervention(s): Genetically Informed Therapy
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Status: Recruiting
Last Changed: Jun 18, 2020
First Received: Mar 24, 2020
Disease(s): Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer
Intervention(s): ACE1702, Cyclophosphamide, Fludarabine
Locations: MD Anderson Cancer Center, Houston, Texas, United States
Peninsula Cancer Institute, Newport News, Virginia, United States
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1
Status: Completed
Last Changed: Mar 10, 2015
First Received: Nov 04, 2010
Disease(s): Solid Tumor
Intervention(s): IMF-001
Locations: Roswell Park Cancer Institute, Buffalo, New York, United States
New York University (NYU) Cancer Center, New York, New York, United States
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
Status: Completed
Last Changed: Sep 27, 2011
First Received: Jan 29, 2008
Disease(s): Advanced Solid Tumors
Intervention(s): OSI-930 and erlotinib
Locations: H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes
Status: Recruiting
Last Changed: Sep 10, 2020
First Received: Nov 21, 2019
Disease(s): Solid Tumor
Intervention(s): Rucaparib
Locations: Innovative Clinical Research Institute, Glendale, California, United States
UCLA Medicine Hematology and Oncology, Los Angeles, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
Florida Cancer Specialists, Saint Petersburg, Florida, United States
... and 17 other locations.
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
Status: Completed
Last Changed: Sep 27, 2012
First Received: Nov 04, 2005
Disease(s): Tumors
Intervention(s): NB1011
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of Minnesota, Minneapolis, Minnesota, United States
Princess Margaret Hospital, Toronto, Ontario, Canada